First human test for new RSV shot begins
NCT ID NCT07289503
Summary
This is an early-stage study to test the safety and immune response of a new, freeze-dried mRNA vaccine designed to protect against Respiratory Syncytial Virus (RSV). It will involve 96 healthy adults who will receive one injection of either the vaccine or a placebo. The main goal is to see how well the vaccine is tolerated and to measure any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baise Center For Disease Control & Prevention
Baise City, Baise, China
Conditions
Explore the condition pages connected to this study.